Rotkreuz (pta007/19.01.2017/08:10) - For the first time, the analysts at Sphene Capital have included the coverage of graceNT AG (WKN A14WW0) and rated its share as a buy. The target price is EUR 60,00 per share; the expected price performance is 103,4% within a period of up to 24 months.
"We are delighted at being included in their coverage and also at the positive rating Sphene Capital have given us. With the Sigmund Freud private university in Vienna being one of the most innovative private universities for psychology and medicine, the opening of our first ALDAVIA® health studio at that very location definitely meets our high standards of quality. With this, we have developed a whole new principle for the personal promotion of one's health," directors and founders Alfred Wegerer and Werner Arrich emphasize.
You can find the research report here:
graceNT AG, based in Rotkreuz/Switzerland, has a vision: a world in which everyone has easy access to personalized medical technology and can therefore age in a healthy, vital and autonomous manner. The company acquires and develops interest in innovative, established producers of medical products in Germany, Austria and Switzerland. graceNT AG invented the triangular "Brain & Body" training concept ALDAVIA®, and is considered a pioneer in the sector of personalized and integrated training concepts for mental and physical fitness. Companies can install ALDAVIA® in-house to deliver occupational psychological and health care to their employees, thus achieving stress reduction and increased personal well-being of their staff.
Thanks to the successful stock exchange listing, clients can also become shareholders in the company and thus be part of an all new, exciting health care system.